Literature DB >> 9721759

Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis.

M B Bogdanov1, L E Ramos, Z Xu, M F Beal.   

Abstract

Mutations in the enzyme copper/zinc superoxide dismutase-1 (SOD1) are associated with familial amyotrophic lateral sclerosis (FALS). The means by which the mutations cause FALS appears to be due to an adverse property of the mutant SOD1 protein that may involve increased generation of free radicals. We used in vivo microdialysis to measure the conversion of 4-hydroxybenzoic acid to 3,4-dihydroxybenzoic acid (3,4-DHBA) as a measure of "hydroxyl radical-like" production in transgenic amyotrophic lateral sclerosis (ALS) mice with the G93A mutation as well as littermate controls. The conversion of 4-hydroxybenzoic acid to 3,4-DHBA was significantly increased in the striatum of transgenic ALS mice at baseline but not in mice overexpressing wild-type human SOD1. Following administration of 3-nitropropionic acid 3,4-DHBA generation was significantly increased as compared with baseline, and the increase in the transgenic ALS mice was significantly greater than those in controls, whereas the increase in mice overexpressing wild-type human SOD1 was significantly attenuated. The present results provide in vivo evidence that expression of mutations in SOD1 can lead to increased generation of "hydroxyl radical-like" activity, which further implicates oxidative damage in the pathogenesis of ALS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721759     DOI: 10.1046/j.1471-4159.1998.71031321.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

1.  5-Aminosalicylic acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro.

Authors:  J Kanski; C Lauderback; D A Butterfield
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

Review 2.  Mitochondria and endoplasmic reticulum crosstalk in amyotrophic lateral sclerosis.

Authors:  Giovanni Manfredi; Hibiki Kawamata
Journal:  Neurobiol Dis       Date:  2015-08-15       Impact factor: 5.996

3.  Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration.

Authors:  Y H Gong; A S Parsadanian; A Andreeva; W D Snider; J L Elliott
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

4.  Infant mice with glutaric acidaemia type I have increased vulnerability to 3-nitropropionic acid toxicity.

Authors:  K B Bjugstad; L S Crnic; S I Goodman; C R Freed
Journal:  J Inherit Metab Dis       Date:  2006-08-30       Impact factor: 4.982

Review 5.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

6.  On the application of 4-hydroxybenzoic acid as a trapping agent to study hydroxyl radical generation during cerebral ischemia and reperfusion.

Authors:  Miao Liu; Shimin Liu; Steven L Peterson; Minoru Miyake; Ke Jian Liu
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 7.  The perplexing role of copper-zinc superoxide dismutase in amyotrophic lateral sclerosis (Lou Gehrig's disease).

Authors:  Soshanna Zittin Potter; Joan Selverstone Valentine
Journal:  J Biol Inorg Chem       Date:  2003-03-19       Impact factor: 3.358

8.  Enhanced free radical generation of FALS-associated Cu,Zn-SOD mutants.

Authors:  M B Yim; H S Yim; P B Chock; E R Stadtman
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

Review 9.  In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models.

Authors:  In-Young Choi; Sang-Pil Lee; David N Guilfoyle; Joseph A Helpern
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

Review 10.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.